The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neumora Therapeutics Inc. shares valued at $239,319 were sold by Fust Matthew K on Oct 18 ’24. At $17.03 per share, Fust Matthew K sold 14,049 shares. The insider’s holdings dropped to 20,100 shares worth approximately $0.25 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Fust Matthew K sold 7,739 shares, netting a total of over 131,643 in proceeds. Following the sale of shares at $17.01 each, the insider now holds 20,100 shares.
Before that, Fust Matthew K had added 14,049 shares to its account. In a trade valued at $239,319, the Director bought Neumora Therapeutics Inc. shares for $17.03 each.
As published in their initiating research note from H.C. Wainwright on October 01, 2024, Neumora Therapeutics Inc. [NMRA] has been a Buy and the price target has been revised to $30. Analysts at Needham started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of July 08, 2024, Mizuho has initiated its “an Outperform” rating for NMRA. Earlier on December 12, 2023, Deutsche Bank initiated its rating. Their recommendation was “a Hold” for NMRA stock.
Analyzing NMRA Stock Performance
During the last five days, there has been a drop of approximately -8.26%. Over the course of the year, Neumora Therapeutics Inc. shares have dropped approximately -28.39%. Shares of the company reached a 52-week high of $21.00 on 03/08/24 and a 52-week low of $8.33 on 06/26/24. A 50-day SMA is recorded $12.94, while a 200-day SMA reached $12.72. Nevertheless, trading volume fell to 0.91 million shares from 1.27 million shares the previous day.
Support And Resistance Levels for Neumora Therapeutics Inc. (NMRA)
According to the 24-hour chart, there is a support level at 11.79, which, if violated, would cause prices to drop to 11.37. In the upper region, resistance lies at 12.45. The next price resistance is at 12.69. RSI (Relative Strength Index) is 39.26 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.33, which suggests the price will decrease in the coming days. Percent R is at 89.24%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
